Glorious Filtration Rate Recovery After a Switch From TDF to TAF or ABC

Rosanne Verwijs1, Ingeborg Witjing3, Marjo van Kasteren2, Jan G. den Hollander3, Inge Derdeelinckx4, Guido van den Berk3, Saskia Vrouwenraets5, Mark Claassen7, Wouter Bierman6, Casper Rokx1, Bart Rijnders1

1Erasmus University Medical Center, Rotterdam, Netherlands, 2Elizabeth-Tweesteden Ziekenhuis, Tilburg, Netherlands, 3Maasstad Hospital, Rotterdam, Netherlands, 4University Hospitals Leuven, Leuven, Belgium, 5OLVG, Amsterdam, Netherlands, 6Slotervaart MC, Amsterdam, Netherlands, 7Rijnstate Hospital, Arnhem, Netherlands; 8University Medical Center Groningen, Groningen, Netherlands.

Results

Of the 215 patients included, 114 switched to TAF and 101 to ABC. eGFR had declined by a mean of 5.1mL/min/yr and 6.7mL/min/yr during a median of 7 and 5 yrs of TDF use respectively. The mean eGFR was 73mL/min at TAF and 67mL/min at ABC initiation, and 22% and 33% had an eGFR <60mL/min.

Week 48 eGFR results (available for 187 pts):

- Significant eGFR increase by 6.7mL/min with TAF and 6.5mL/min with ABC (p<0.001 compared to baseline for both, p=0.1 for TAF versus ABC).
- >50% eGFR recovery observed in 28/100 (28%) and 23/85 (27%) respectively (p=0.1).

In 23 of 46 patients with w48 results available and eGFR>60 at TDF discontinuation, a recovery to >60mL/min was observed.

More patients discontinued ABC than TAF (11% vs 2%, p=0.008) and this was mostly driven by discontinuations for drug-related AE (10% vs 2%, p=0.014).

HIV-RNA remained suppressed in all but 2 patients.

Methods

We performed a retrospective cohort study in 7 Dutch and 1 Belgian center in which patients were included if they had switched from TDF to TAF or ABC for a significant eGFR decline:

- eGFR decline of >3mL/min/yr during ≥5yrs of TDF use or
- >25% eGFR decline or
- eGFR<70mL/min with eGFR<90mL/min at TDF initiation

To exclude other possible causes of the eGFR decline as much as possible (whether HIV related on unrelated), patients with any of the following were excluded: Detectable HIV-RNA, diabetes, history of cardiovascular disease, uncontrolled hypertension, use of ≥1 antihypertensive drug, use of potentially nephotoxic medication, HBV/HCV coinfection or any diagnosed kidney disease that may partially explain the eGFR decline.

To correct for the inhibition of the tubular export of creatinine by rilpivirine, dolasetrigrav or cobicistat we added +10mL/min to the measured eGFR if any of these drugs were started together with ABC or TAF.

Primary endpoint: eGFR recovery of >50% at week 48 after TDF discontinuation

<table>
<thead>
<tr>
<th>Baseline characteristics</th>
<th>ABC (n=101)</th>
<th>TAF (n=114)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male sex (N (%))</td>
<td>80 (79.2%)</td>
<td>98 (86.0%)</td>
</tr>
<tr>
<td>Age</td>
<td>50 (±11)</td>
<td>52 (±38)</td>
</tr>
<tr>
<td>eGFR at TDF initiation mL/min*</td>
<td>103 (±17)</td>
<td>108 (±17)</td>
</tr>
<tr>
<td>eGFR at TDF discontinuation mL/min*</td>
<td>67 (±15)</td>
<td>73 (±15)</td>
</tr>
<tr>
<td>Duration of TDF use in yrs†</td>
<td>3 (7, 9)</td>
<td>7 (4, 9)</td>
</tr>
<tr>
<td>eGFR&gt;60 mL/min at TDF discontinuation (N (%))</td>
<td>33 (32.7%)</td>
<td>25 (21.9%)</td>
</tr>
</tbody>
</table>

Table 1. Baseline demographic characteristics and eGFR decline during TDF use.

*Mean (±SD), †Median (IQR)

Discussion

Strengths:

- Selection to exclude patients with other possible causes for eGFR decline
- Relatively large patient population with clinically relevant eGFR decline during TDF use

Limitations:

- TDF as cause for eGFR decline can never be proven
- Follow up still relatively short: Further recovery?
- Baseline differences between ABC and TAF groups
- BACTAF prospective randomized controlled trial
- Multivariable analysis with W96 follow up planned

Conclusion

Although a modest improvement in eGFR was observed after TDF discontinuation, few patients recovered >50% of their eGFR one year after TDF discontinuation. The recovery rate in patients that switched to TAF and ABC was comparable.

This study was supported by a research grant from Gilead Sciences.